(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Blue Origin launches huge rocket carrying twin NASA spacecraft to Mars - 2Cases of norovirus are on the rise just in time for the holiday season
- 37 Fast Approaches to Let loose Space on Your Telephone in a flash
- 4Floods, Landslides Triggered By Heavy Rain In Afghanistan Leave 77 Dead In 10 days, Authorities Say
- 5‘Dying of thirst’: Inside Gaza’s al-Mawasi water crisis
- Tremendous Spelunking: Cool Caverns All over the Planet
- This St Nick Truly Can Advise How To Drink And Hack Your Headache
- I’m a dad to an autistic child. Here’s how you can make the holidays easier for all of us.
- ‘Aid for Ukraine’ pierogi fundraiser event
- How the Iran war may affect your money and bills
- Esteem Stuffed Gaming Workstations to Consider
- Europe: 4 Urban communities for a Paramount Social Experience
- Baidu robotaxi outage in Wuhan caused by 'system failure', police say
- Flu cases spiking this holiday season, CDC data shows
